The American pharmaceutical company Eli Lilly is completely leaving Russia
[ad_1]
The American pharmaceutical company Eli Lilly has decided to completely withdraw from the Russian market, transferring its business in Russia to its partner in Central and Eastern Europe, Swixx Biopharma. “Kommersant” writes about it.
According to two former employees of Eli Lilly’s Russian division, preparations for the transfer of the Russian business began at the end of February.
As the interlocutors of the publication noted, Swixx Biopharma is likely to distribute those drugs that Eli Lilly continued to supply to Russia after the announcement an hour ago about the suspension of the export of its products to the Russian market. Then the company promised to preserve supplies of Humalog insulin, the anti-diabetic drug Trulysity, and the oncological drugs Zenlystyk, Tsyramza, Alimta, and Gemzar.
Eli Lilly is already the second large American pharmaceutical company to leave the Russian market amid Russia’s war against Ukraine and transfer its business to the management of Swixx Biopharma. In May last year, the American Bristol-Myers Squibb did exactly the same thing.
After the beginning of the Russian military invasion of Ukraine, several large foreign pharmaceutical companies limited their work in Russia. Yes, Gilead has suspended all non-life-saving drug operations. Pfizer, Bayer, Novartis, MSD, Sanofi and AbbVie continue to supply drugs, but have suspended investment or clinical research.
[ad_2]
Original Source Link
